Sarcopenia is associated with short‐ and long‐term mortality in patients with acute‐on‐chronic liver failure

While sarcopenia is recognized as a predictor of mortality in cirrhosis, its influence on acute‐on‐chronic liver failure (ACLF) remains uncertain. Despite multiple studies examining the impact of sarcopenia on short‐term mortality in patients with ACLF, the sample size of these studies was limited, and their outcomes were inconsistent. Therefore, this study aimed to explore the impact of sarcopenia on both short‐ and long‐term mortality in patients with ACLF. This retrospective cohort study included 414 patients with ACLF that were treated between January 2016 and September 2022. Sarcopenia was diagnosed based on the measurement of the skeletal muscle index at the third lumbar vertebra (L3‐SMI). Subsequently, the patients were divided into sarcopenia and non‐sarcopenia groups. We analysed the basic clinical data of the two groups. Multivariate Cox proportional analysis was used to analyse short‐term (28 days) and long‐term (1 year and overall) mortality rates. A total of 414 patients were included, with a mean age of 52.88 ± 13.41 years. Among them, 318 (76.8%) were male, and 239 (57.7%) had sarcopenia. A total of 280 (67.6%) patients died during the study period. Among them, 153 patients died within 28 days (37%) and 209 patients died within 1 year (50.5%). We found that the 28‐day, 1‐year and overall mortality rates in the sarcopenia group were significantly higher than those in the non‐sarcopenia group (37% vs. 22.3%, P< 0.01; 50.5% vs. 34.9%, P< 0.01; and 67.6% vs. 53.1%, P< 0.01, respectively). Multivariate Cox regression analysis revealed that sarcopenia was significantly associated with increased mortality. The hazard ratios for sarcopenia were 2.05 (95% confidence interval [CI] 1.41–3.00, P< 0.01) for 28‐day mortality, 1.81 (95% CI 1.29–2.54, P< 0.01) for 1‐year mortality and 1.82 (95% CI 1.30–2.55, P< 0.01) for overall mortality. In addition, muscle density and international normalized ratio were associated with short‐ and long‐term mortality. Sarcopenia is associated with both short‐ and long‐term mortality in patients with ACLF. Therefore, regular monitoring for sarcopenia is important for these patients.